Article Details

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid ...

Retrieved on: 2020-12-21 07:41:15

Tags for this article:

Click the tags to see associated articles and topics

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid .... View article details on hiswai:

Excerpt

The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up